Multicenter phase II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel therapy for patients with resectable pancreatic cancer. - Multicenter phase II study of neoadjuvant GEM+nab-PTX for resectable pancreatic cancer.

Division of Hepato-biliary-pancreatic Surgery Department of Surgery, Kobe University Graduate School of Medicine0 sites45 target enrollmentAugust 15, 2017

ConditionsInvasive ductal adenocarcinoma

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Invasive ductal adenocarcinoma
Sponsor: Division of Hepato-biliary-pancreatic Surgery Department of Surgery, Kobe University Graduate School of Medicine
Enrollment: 45
Status: Not yet recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

August 15, 2017

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Division of Hepato-biliary-pancreatic Surgery Department of Surgery, Kobe University Graduate School of Medicine

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\. History of gemcitabine, nab\-paclitaxel 2\. Ongoing active other malignancy 3\. Allergic to gemcitabine and nab\- 4\. Computed tomography contrast media allergy 5\. poor control of diarrhea 6\. Intestinal pneumonia 7\. Moderate amount of ascites or pleural effusion 8\. Active infection 9\. Poor control of diabetes mellitus 10\. Serious comorbid conditions 11\.Myocardial infarction within last 6 months 12\. Systemic steroid therapy 13\. Serious psychiatric diseases 14\. Planning a baby or pregnancy 15\. Planning a baby 16\. Judged unable to guarantee safety